Zeng Wang
Jilin University
6 Papers
12 Citations
Zeng Wang is an academic researcher from Jilin University. The author has contributed to research in topics: Liposome & Medicine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity.
Bing Han,Yue Yang,Yue Yang,Jinglin Chen,Huan Tang,Yuxin Sun,Zheng Zhang,Zeng Wang,Yan Li,Yao Li,Xue Luan,Qianwen Li,Zhihui Ren,Xiaowei Zhou,Dengli Cong,Zhiyi Liu,Qin Meng,Fei Sun,Jin Pei +18 more
TL;DR: ES-SSL-PTX could significantly prolong the half-life of the drug, increase its circulation time in vivo, improve its bioavailability and reduce its toxicity and side effects, and has great potential for improving the treatment of breast cancer.
•Journal Article
Effects of Acanthopanax senticosus polysaccharide on the proliferation, apoptosis and cell cycle in human HepG2 cells.
TL;DR: Results indicate that ASPS has a certain inhibition on the proliferation, can induce the apoptosis and G0/G1 phase arrest in HepG2 cells, and the mechanism may be related to the inhibition of ASPS on the activation of Wnt/β-catenin pathway HepG1 cells.
14
Estrone-targeted PEGylated Liposomal Nanoparticles for Cisplatin (DDP) Delivery in Cervical Cancer.
Qi-an Li,Ming-xi Zhu,Yao Li,Hua Tang,Zeng Wang,Yan Qiu Zhang,Yizhuo Xie,Zhe Lv,Han Bao,Yang Li,Ruiqiang Li,Yu J. Shen,Yu-Rong Zheng,Dongfanghui Miao,Xinle Guo,Jin Pei +15 more
TL;DR: In this paper , estrone-targeted PEGylated Liposomal DDP (ES-SSL-DDP) was prepared by thin-film hydration method and characterized.
9
Patent
Mitoxantrone estrogen targeting PEG-modified liposome and applications thereof
Pei Jin,Guoxing Xu,Hao Qiang,Gao Haicheng,Yue Yang,Zeng Wang,Yuxin Sun,Zheng Zhang,Dengli Cong,Duan Minghua +9 more
- 14 Oct 2015
TL;DR: In this article, a preparation method and uses of an anti-cancer drug estrogen targeting PEG-modified liposome was revealed. But the method was not suitable for breast cancer, leukemia and other cancers.
1
Patent
Application of novel liposome-entrapped mitoxantrone combined chemotherapeutic drug in antineoplastic treatment
Jin Pei,Bing Han,Hao Qiang,Zheng Zhang,Song Liping,Dengli Cong,Yan Li,Lin Tian,Yue Yang,Zeng Wang,Yuxin Sun,Jinglin Chen +11 more
- 03 Feb 2016
TL;DR: In this paper, a novel liposome-entrapped mitoxantrone combined chemotherapeutic drug in antineoplastic treatment is presented, which has the characteristics of high entrapment rate, uniform particle size distribution, good stability, prolongation of chemotherAPEutics half life, and reduction of toxic and side effect.